Sequence Diversification by Divergent C-Terminal Elongation of Peptides

Christine A. Arbour,[†] Ramona E. Stamatin,[†] and Jennifer L. Stockdill*

Department of Chemistry, Wayne State University, 5101 Cass Avenue, Detroit, MI 48202, United States

Table of Contents

Table 1. Solution phase C-terminal elongation	S2
Table 2. On-resin elongation	S11
Table 3. Evaluation of alanine epimerization	S38
Table 4. Elongation of LYRAGLRAY	S46
Table SI-01. Evaluation of alanine epimerization using alcohol co-solvents	S60
Table 5. Side-chain protected amino acid elongation of LYRAGLRAY	S64
¹ H and ¹³ C NMR Spectra	S71

[†] These authors contributed equally to this work.






Table 1, entry 1: 10 equiv H-Gly-OH was weighed out into a vial containing a stir bar. 20 mg of crude peptide (**5**, 35 μ mol) was dissolved in 300 μ L of (2:1) MeCN:H₂O and added to the amino acid containing vial. 11 equiv of freshly distilled DIEA was added to the vial and allowed to stir at ambient temperature for 30 min. After 30 min, the reactions were quenched in 20% MeCN/H₂O (1% TFA) and analyzed via RP-HPLC-MS.




Figure SI-01. Reaction progress after 30 min of H-Gly-OH addition, Gradient: 20-45(12 min)-95(3 min)% MeCN/H₂O (0.1% HCOOH) over 15 min.




Table 1, entry 2: 10 equiv H-Ala-OH was weighed out into a vial containing a stir bar. 20 mg of crude peptide (5, 35 μ mol) was dissolved in 300 μ L of (2:1) MeCN:H₂O and added to the amino acid containing vial. 11 equiv of freshly distilled DIEA was added to the vial and allowed to stir at ambient temperature for 30 min. After 30 min, the reactions were quenched in 20% MeCN/H₂O (1% TFA) and analyzed via RP-HPLC-MS.




Figure SI-02. Reaction progress after 30 min of H-Ala-OH addition, Gradient: 20-45(12 min)-95(3 min)% MeCN/H₂O (0.1% HCOOH) over 15 min.




Table 1, entry 3: 10 equiv H-Pro-OH was weighed out into a vial containing a stir bar. 20 mg of crude peptide (5, 35 μ mol) was dissolved in 300 μ L of (2:1) MeCN:H₂O and added to the amino acid containing vial. 11 equiv of freshly distilled DIEA was added to the vial and allowed to stir at ambient temperature for 6 h, after 6 h the reactions were quenched in 20% MeCN/H₂O (1% TFA) and analyzed via RP-HPLC-MS.




Figure SI-03. Reaction progress after 6 h of H-Pro-OH addition, Gradient: 20-45(12 min)-95(3 min)% MeCN/H₂O (0.1% HCOOH) over 15 min.




Table 1, entry 4: 10 equiv H-IIe-OH was weighed out into a vial containing a stir bar. 20 mg of crude peptide (5, 35 μ mol) was dissolved in 300 μ L of (2:1) MeCN:H₂O and added to the amino acid containing vial. 11 equiv of freshly distilled DIEA was added to the vial and allowed to stir at ambient temperature for 30 min. After 30 min, the reactions were quenched in 20% MeCN/H₂O (1% TFA) and analyzed via RP-HPLC-MS.




Figure SI-04. Reaction progress after 1 h of H-Ile-OH addition, Gradient: 20-45(12 min)-95(3 min)% MeCN/H₂O (0.1% HCOOH) over 15 min.




Table 1, entry 5: 10 equiv H-Trp-OH was weighed out into a vial containing a stir bar. 20 mg of crude peptide (5, 35 μ mol) was dissolved in 300 μ L of (2:1) MeCN:H₂O and added to the amino acid containing vial. 11 equiv of freshly distilled DIEA was added to the vial and allowed to stir at ambient temperature for 30 min. After 30 min, the reactions were quenched in 20% MeCN/H₂O (1% TFA) and analyzed via RP-HPLC-MS.




Figure SI-05. Reaction progress after 30 min of H-Trp-OH addition, gradient: 20-45(12 min)-95(3 min)% MeCN/H₂O (0.1% HCOOH) over 15 min.




Table 1, entry 6: 10 equiv of H-Gly-OH was weighed out into a vial containing a stir bar. 20 mg of **7** (25 μ mol) was dissolved in 300 μ L of (2:1) MeCN:H₂O and added to the amino acid. Then 11 equiv of freshly distilled DIEA was added and allowed to stir at ambient temperature for 30 min. The reactions were quenched in 20% MeCN/H₂O (1% TFA) and analyzed via RP-HPLC-MS.




Figure SI-06. Reaction progress after 30 m of H-Gly-OH addition, gradient: 20-45(12 min)-95(3 min)% MeCN/H₂O (0.1% HCOOH) over 15 min.




Table 1, entry 7: 10 equiv of H-Ala-OH was weighed out into a vial containing a stir bar. 20 mg of **7** (25 μ mol) was dissolved in 300 μ L of (2:1) MeCN:H₂O and added to the amino acid. Then 11 equiv of freshly distilled DIEA was added and allowed to stir at ambient temperature for 30 min. The reactions were quenched in 20% MeCN/H₂O (1% TFA) and analyzed via RP-HPLC-MS.




Figure SI-07. Reaction progress after 30 m of H-Ala-OH addition, Gradient: 20-45(12 min)-95(3 min)% MeCN/H₂O (0.1% HCOOH) over 15 min.




Table 1, entry 8: 10 equiv of H-IIe-OH was weighed out into a vial containing a stir bar. 20 mg of **7** (25 μ mol) was dissolved in 300 μ L of (2:1) MeCN:H₂O and added to the amino acid. Then 11 equiv of freshly distilled DIEA was added and allowed to stir at ambient temperature for 30 min. The reactions were quenched in 20% MeCN/H₂O (1% TFA) and analyzed via RP-HPLC-MS.




Figure SI-08. Reaction progress after 2 h of H-Ile-OH addition, Gradient: 20-45(12 min)-95(3 min)% MeCN/H₂O (0.1% HCOOH) over 15 min.




Table 1, entry 9: 10 equiv of H-Pro-OH was weighed out into a vial containing a stir bar. 20 mg of **7** (25 μ mol) was dissolved in 300 μ L of (2:1) MeCN:H₂O and added to the amino acid. Then 11 equiv of freshly distilled DIEA was added and allowed to stir at ambient temperature for 30 min. The reactions were quenched in 20% MeCN/H₂O (1% TFA) and analyzed via RP-HPLC-MS. Only macrocycle was observed.





Figure SI-09. Reaction progress after 6 h of H-Pro-OH addition, Gradient: 20-45(12 min)-95(3 min)% MeCN/H₂O (0.1% HCOOH) over 15 min.






Table 2, entry 1: 20 mg of **9** (4 μ mol) was weighed out into a 2 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-Gly-OH was dissolved in 500 μ L DMF in a separate vial and added to the swelled resin. Then 11 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide.




Figure SI-10. Analytical Column PDA of crude peptide at 254 nm. Gradient: 40-95(10 min)-95(5 min)% MeCN/H₂O (0.1% HCOOH).




Figure SI-11. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.




Table 2, entry 2: 20 mg of **9** (4 μ mol) was weighed out into a 2 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-Gly-OH was dissolved in 500 μ L DMF in a separate vial and added to the swelled resin. Then 11 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide.




Figure SI-12. Analytical Column PDA of crude peptide at 254 nm. Gradient: 40-95(10 min)-95(5 min)% MeCN/H₂O (0.1% HCOOH).




Figure SI-13. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.




Table 2, entry 3: 20 mg of **9** (4 μ mol) was weighed out into a 2 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-Gly-OH was added directly to the resin followed by 600 μ L DMF:H₂O (5:1). Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide.




Figure SI-14. Analytical Column PDA of crude peptide at 254 nm. Gradient: 40-95(10 min)-95(5 min)% MeCN/H₂O (0.1% HCOOH).




Figure SI-15. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O over 15 min (0.1% HCOOH).




Table 2, entry 4: 20 mg of **9** (4 μ mol) was weighed out into a 2 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure).10 equiv of H-Gly-OH and 1 equiv of NaSPh were added directly to the resin followed by 600 μ L DMF:H₂O (5:1) with 100 μ L of ethyl-3-mercaptopropionate. Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide. Exclusively alkyl thioester was observed.

MS Chromatogram(RES-I-075 crude.lcd)




Figure SI-16. Analytical Column PDA of crude peptide at 254 nm. Gradient: 40-95(10 min)-95(5 min)% MeCN/H₂O (0.1% HCOOH).




Figure SI-17. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.




Table 2, entry 5: 20 mg of **9** (4 μ mol) was weighed out into a 2 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-Gly-OH and 1 equiv of NaSPh were added directly to the resin followed by 600 μ L DMF:H₂O (5:1). Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide.




Figure SI-18. Analytical Column PDA of crude peptide at 254 nm. Gradient: 40-95(10 min)-95(5 min)% MeCN/H₂O (0.1% HCOOH).




Figure SI-19. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.





Table 2. entry 5: 100 mg (16 µmol) of 9 was weighed out into a 5 mL reaction vial and swelled in 500 µL CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-Gly-OH and 1 equiv of NaSPh were added directly to the resin followed by 600 μ L DMF:H₂O (5:1). Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial and guenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN_2) , and lyophilized to yield the crude peptide. The crude peptide was purified using RP-HPLC-MS to yield the pure peptide 10a-G-OH in 39% yield (4.7 mg). ¹H NMR (600 MHz, DMSO- d_6) δ 8.12 (s, 1H), 7.98 (dd, J = 33.3, 7.4 Hz, 1H), 7.81 (d, J = 7.9 Hz, 1H), 7.67 (d, J = 8.2 Hz, 1H), 7.47 (s, 1H), 7.30 (q, J = 7.2, 6.7 Hz, 1H), 7.23 (q, J = 6.8 Hz, 1H), 6.96 (dd, J = 27.6, 7.2 Hz, 1H), 4.58 (dd, J = 14.0, 5.8 Hz, 1H), 4.36 - 4.25 (m, 1H), 3.91 - 3.84 (m, 1H), 3.79 - 3.68 (m, 3H), 3.11 (d, J = 11.0 Hz, 1H), 2.93 (dd, J = 14.9, 8.3 Hz, 1H), 1.60 (s, 9H), 1.34 (s, 8H), 1.21 (d, J = 7.0 Hz, 2H), 1.11 (dq, J = 16.0, 9.0, 8.1 Hz, 4H). ¹³C NMR (151 MHz, DMSO) δ 172.6, 172.3, 171.1, 170.5, 155.0, 149.1, 134.7, 130.4, 124.2, 122.4, 119.5, 116.1, 114.5, 83.4, 78.2, 52.4, 51.9, 50.1, 48.1, 40.8, 28.2, 27.7, 18.3, 18.1. HRMS (ESI+) m/z calc'd for C₂₉H₄₁N₅O₉Na [M+Na]⁺ 626.2802, found 626.2786.



(0.1% HCOOH).

MS Chromatogram(RES-I-086 TFAcleavage 20-80-15m C18-3.10.lcd)




Figure SI-21. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.




Figure SI-22. Analytical Column PDA of pure peptide, gradient of 40-95(10 min)-95(5 min)% MeCN/H₂O (0.1% HCOOH) over 15 min.




Table 2, entry 6: 20 mg of **9** (4 μ mol) was weighed out into a 2 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-IIe-OH was dissolved in 500 μ L DMF and 100 μ L H₂O in a separate vial and added to the swelled resin. Then 11 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide.




Figure SI-23. Analytical Column PDA of crude peptide at 254 nm. Gradient: 40-95(10 min)-95(5 min)% MeCN/H₂O (0.1% HCOOH).




Figure SI-24. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.




Table 2, entry 7: 20 mg of **9** (4 μ mol) was weighed out into a 2 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-IIe-OH was added directly to the resin followed by 600 μ L DMF:H₂O (5:1). Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide.




Figure SI-25. Analytical Column PDA of crude peptide at 254 nm. Gradient: 40-95(10 min)-95(5 min)% MeCN/H₂O (0.1% HCOOH).




Figure SI-26. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.




Table 2, Entry 8: 20 mg of **9** (4 μ mol) was weighed out into a 2 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-IIe-OH and 1 equiv of NaSPh was added directly to the resin followed by 600 μ L DMF:H₂O (5:1). Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide.




Figure SI-27. Analytical Column PDA of crude peptide at 254 nm. Gradient: 40-95(10 min)-95(5 min)% MeCN/H₂O (0.1% HCOOH).




Figure SI-28. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.




Table 2, entry SI-01: 20 mg of **9** (4 μ mol) was weighed out into a 2 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. A fresh sodium phosphate buffer was prepared (see sodium phosphate buffer with guanidine procedure). After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-IIe-OH and 1 equiv of NaSPh were added directly to the resin followed by 600 μ L DMF: modified NCL buffer (5:1). Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide. Mostly guanidine addition was observed.




Figure SI-29. Analytical Column PDA of crude peptide at 254 nm. Gradient: 40-95(10 min)-95(5 min)% MeCN/H₂O (0.1% HCOOH).




Figure SI-30. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.




Table 2, entry 9: 100 mg of 9 (16 μ mol) was weighed out into a 2 mL reaction vial and swelled in 500 µL CH₂Cl₂ for 30 min. A fresh sodium phosphate buffer was prepared (see Sodium phosphate buffer, guanidine-free). After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-Ile-OH and 1 equiv of NaSPh were added directly to the resin followed by 600 μ L DMF:NCL Buffer (5:1). Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial and guenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide. The crude peptide was purified using RP-HPLC-MS to give the pure peptide in 22% yield (4.4 mg). ¹H NMR (499 MHz, DMSO- d_6) δ 8.21 (d, J = 7.1 Hz, 1H), 8.01 (d, J = 8.0 Hz, 1H), 7.88 (d, J = 8.2 Hz, 1H), 7.83 (d, J = 8.0 Hz, 1H), 7.65 (d, J = 7.6 Hz, 1H), 7.49 (s, 1H), 7.29 (t, J = 7.7 Hz, 1H), 7.21 (t, J = 7.5 Hz, 1H), 6.92 (d, J = 7.3 Hz, 1H), 4.66 – 4.53 (m, 1H), 4.37 (g, J = 7.5 Hz, 1H), 4.66 – 4.53 (m, 1H), 4.37 (g, J = 7.5 Hz, 1H), 4.66 – 4.53 (m, 1H), 4.67 (g, J = 7.5 Hz, 1H), 4.66 – 4.53 (m, 1H), 4.67 (g, J = 7.5 Hz, 1H), 4.66 – 4.53 (m, 1H), 4.67 (g, J = 7.5 Hz, 1H), 4.66 – 4.53 (m, 1H), 4.67 (g, J = 7.5 Hz, 1H), 4.66 – 4.53 (m, 1H), 4.67 (g, J = 7.5 Hz, 1H), 4.66 – 4.53 (m, 1H), 4.67 (g, J = 7.5 Hz, 1H), 4.66 – 4.53 (m, 1H), 4.67 (g, J = 7.5 Hz, 1H), 4.67 (g, J = 7.5 Hz, 1H), 4.67 (g, J = 7.5 Hz, 1H), 4.68 – 4.53 (m, 1H), 4.67 (g, J = 7.5 Hz, 1H), 4.68 – 4.53 (m, 1H), 4.67 (g, J = 7.5 Hz, 1H), 4.68 – 4.53 (m, 1H), 4.67 (g, J = 7.5 Hz, 1H), 4.68 – 4.53 (m, 1H), 4.68 (m, 1H), 4.57 (m, 2H) 6.9 Hz, 1H), 4.17 (dd, J = 8.2, 5.8 Hz, 1H), 3.92 – 3.83 (m, 1H), 3.13 – 3.02 (m, 1H), 2.97 – 2.87 (m, 1H), 1.76 (dq, J = 13.7, 7.7, 7.2 Hz, 1H), 1.60 (s, 9H), 1.33 (s, 8H), 1.20 (t, J = 6.9 Hz, 3H), 1.10 (d, J = 7.0 Hz, 4H), 0.84 (t, J = 7.8 Hz, 6H). ¹³C NMR (126 MHz, DMSO) δ 172.9, 172.6, 172.1, 170.6, 155.0, 149.1, 134.7, 130.4, 124.2, 122.4, 119.4, 116.2, 114.6, 83.4, 78.2, 56.3, 51.8, 50.2, 48.0, 36.5, 28.2, 27.7, 27.4, 24.7, 18.2, 15.6, 11.4; HRMS (ESI+) m/z calc'd for $C_{33}H_{49}N_5O_9Na [M+Na]^+ 682.3428$, found 682.3428.




Figure SI-31. Analytical Column PDA of crude peptide at 254 nm. Gradient: 40-95(10 min)-95(5 min)% MeCN/H₂O (0.1% HCOOH).




Figure SI-32. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.




Figure SI-33. Analytical Column PDA of pure peptide, gradient of 40-95(10 min)-95(5 min)% MeCN/H₂O (0.1% HCOOH) over 15 min.




Table 2, entry 10: 20 mg of **9** was weighed out into a 2 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-Ala-OH was dissolved in 500 μ L DMF and 100 μ L H₂O in a separate vial and added to the swelled resin. Then 11 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide.




Figure SI-34. Analytical Column PDA of crude peptide at 254 nm. Gradient: 40-95(10 min)-95(5 min)% MeCN/H₂O (0.1% HCOOH).




Figure SI-35. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.






Table 2, entry 11: 20 mg of **9** (4 μ mol) was weighed out into a 2 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-Ala-OH was added directly to the resin followed by 600 μ L DMF:H₂O (5:1). Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide.








Figure SI-37. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.




Table 2, entry 12: 20 mg of **9** (4 μ mol) was weighed out into a 2 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-Ala-OH and 1 equiv of NaSPh was added directly to the resin followed by 600 μ L DMF:H₂O (5:1). Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide.




Figure SI-38. Analytical Column PDA of crude peptide at 254 nm. Gradient: 40-95(10 min)-95(5 min)% MeCN/H₂O (0.1% HCOOH).




Figure SI-39. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.






Table 2, entry SI-02: 20 mg of **9** (4 μ mol) was weighed out into a 2 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. A fresh sodium phosphate buffer was prepared. (See Sodium phosphate buffer with guanidine procedure). After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-Ala-OH and 1 equiv of NaSPh were added directly to the resin followed by 600 μ L DMF:modified NCL Buffer (5:1). Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide. Mostly guanidine addition was observed.








Figure SI-41. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.




Table 2, entry 13: 100 mg of 9 (16 µmol) was weighed out into a 5 mL reaction vial and swelled in 500 µL CH₂Cl₂ for 30 min. A fresh sodium phosphate buffer was prepared. (See Sodium phosphate buffer (Guanidine-free) procedure). After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-Ala-OH and 1 equiv of NaSPh were added directly to the resin followed by 600 μ L DMF:modified NCL Buffer (5:1). Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial and guenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN_2), and lyophilized to yield the crude peptide. The crude peptide was purified using RP-HPLC-MS to isolate 2.3 mg of pure peptide and 5.2 mg of mixed peptide (61% HPLC purity) to give 29% yield. ¹H NMR (600 MHz, DMSO- d_6) δ 8.20 (s, 1H), 8.01 (d, J = 7.6 Hz, 1H), 7.80 (d, J = 7.8 Hz, 1H), 7.67 (s, 1H), 7.48 (s, 1H), 7.30 (t, J = 7.5 Hz, 1H), 7.26 – 7.18 (m, 1H), 6.94 (d, J = 6.4 Hz, 1H), 4.59 (s, 1H), 4.28 (d, J) = 6.4 Hz, 1H), 4.59 (s, 1H), 4.28 (d, J) = 6.4 Hz, 1H), 4.59 (s, 1H), 4.28 (d, J) = 6.4 Hz, 1H), 4.59 (s, 1H), 4.28 (d, J) = 6.4 Hz, 1H), 4.59 (s, 1H), 4.28 (d, J) = 6.4 Hz, 1H), 4.59 (s, 1H), 4.28 (d, J) = 6.4 Hz, 1H), 4.59 (s, 1H), 4.28 (d, J) = 6.4 Hz, 1H), 4.59 (s, 1H), 4.28 (d, J) = 6.4 Hz, 1H), 4.59 (s, 1H), 4.28 (d, J) = 6.4 Hz, 1H), 4.59 (s, 1H), 4.28 (d, J) = 6.4 Hz, 1H), 4.59 (s, 1H), 4.28 (d, J) = 6.4 Hz, 1H), 4.59 (s, 1H), 4.28 (d, J) = 6.4 Hz, 1H), 4.59 (s, 1H), 4.28 (d, J) = 6.4 Hz, 1H), 4.59 (s, 1H), 4.28 (d, J) = 6.4 Hz, 1H), 4.59 (s, 1H), 4.28 (d, J) = 6.4 Hz, 1H), 4.59 (s, 1H), 4.28 (d, J) = 6.4 Hz, 1H), 4.59 (s, 1H), 4.28 (d, J) = 6.4 Hz, 1H), 4.59 (s, 1H), 4.28 (d, J) = 6.4 Hz, 1H), 6.51 (s, 1H), 6.5 J = 6.6 Hz, 1H), 4.16 (s, 1H), 3.90 – 3.85 (m, 1H), 3.08 (s, 1H), 2.92 (dd, J = 14.8, 8.3 Hz, 1H), 1.60 (s, 9H), 1.33 (s, 7H), 1.28 – 1.22 (m, 3H), 1.19 (d, *J* = 6.9 Hz, 3H), 1.10 (d, *J* = 7.3 Hz, 4H). ¹³C NMR (151 MHz, DMSO) δ 174.0, 172.6, 171.6, 170.4, 155.0, 149.1, 134.7, 130.4, 124.2, 122.4, 119.5, 116.2, 114.6, 83.4, 78.2, 51.9, 50.1, 47.9, 47.6, 28.2, 27.7, 18.2, 18.08, 17.3. HRMS (ESI+) m/z calc'd for C₃₀H₄₃N₅O₉Na [M+Na]⁺ 640.2958, found 640.2940.






Figure SI-42. Analytical Column PDA of crude peptide at 254 nm. Gradient: 40-95(10 min)-95(5 min)% MeCN/H₂O (0.1% HCOOH).





MS Chromatogram(RES-II-004_pure_40-95-95-15m_C18-3.6.lcd)




Figure SI-44. Analytical Column PDA of pure peptide, gradient of 40-95(10 min)-95(5 min)% MeCN/H₂O (0.1% HCOOH) over 15 min.




Figure SI-45. Analytical Column PDA of mixed peptides, gradient of 40-95(10 min)-95(5 min)% MeCN/H₂O (0.1% HCOOH) over 15 min.




Table 2, entry 14: 20 mg of **9** (4 μ mol) was weighed out into a 2 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-Pro-OH was dissolved in 500 μ L DMF and 100 μ L H₂O in a separate vial and added to the swelled resin. Then 11 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide.




Figure SI-46. Analytical Column PDA of crude peptide at 254 nm. Gradient: 40-95(10 min)-95(5 min)% MeCN/H₂O (0.1% HCOOH).




Figure SI-47. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.




Table 2, entry 15a: 20 mg of **9** (4 μ mol) was weighed out into a 2 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-Pro-OH was added directly to the resin followed by 600 μ L DMF:H₂O (5:1). Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide.




Figure SI-48. Analytical Column PDA of crude peptide at 254 nm. Gradient: 40-95(10 min)-95(5 min)% MeCN/H₂O (0.1% HCOOH).




Figure SI-49. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.






Table 2, entry 15b: 100 mg of **9** (16 μ mol) was weighed out into a 5 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-Pro-OH was added directly to the resin followed by 600 μ L DMF:H₂O (5:1). Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the

remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide. The crude peptide was purified using RP-HPLC-MS yielding 1 mg of pure peptide (**10a-P-OH**) and 5.9 mg of mixed peptide (79% HPLC purity) giving 44% yield. ¹H NMR (499 MHz, DMSO-*d*₆) δ 12.43 (s, 1H), 8.23 (d, *J* = 7.1 Hz, 1H), 8.01 (d, *J* = 8.1 Hz, 1H), 7.81 (d, *J* = 8.0 Hz, 1H), 7.65 (d, *J* = 7.8 Hz, 1H), 7.48 (s, 1H), 7.30 (t, *J* = 7.2 Hz, 1H), 7.22 (t, *J* = 7.5 Hz, 1H), 6.93 (d, *J* = 7.4 Hz, 1H), 4.60 (d, *J* = 5.8 Hz, 1H), 4.53 – 4.43 (m, 1H), 4.23 (dd, *J* = 8.8, 4.1 Hz, 1H), 3.96 – 3.84 (m, 1H), 3.49 (d, *J* = 6.7 Hz, 2H), 3.11 – 2.98 (m, 1H), 2.91 (dd, *J* = 13.9, 7.6 Hz, 1H), 2.18 – 2.04 (m, 1H), 1.94 – 1.77 (m, 3H), 1.61 (s, 9H), 1.35 (s, 8H), 1.18 (d, *J* = 6.7 Hz, 3H), 1.11 (d, *J* = 7.0 Hz, 3H). ¹³C NMR (151 MHz, DMSO) δ 173.3, 172.5, 170.0, 155.0, 149.1, 134.6, 130.4, 124.2, 122.3, 119.4, 116.1, 114.6, 83.4, 78.2, 59.7, 58.6, 51.9, 50.0, 49.5, 46.3, 28.6, 28.2, 27.7, 24.5, 18.1, 16.9. HRMS (ESI+) *m/z* calc'd for C₃₂H₄₅N₅O₉Na [M+Na]⁺ 666.3115, found 666.3115.








Figure SI-51. Analytical Column PDA of mixed peptide, gradient of 40-95(10 min)-95(5 min)% MeCN/H₂O (0.1% HCOOH) over 15 min.




Figure SI-52. Analytical Column PDA of pure peptide, gradient of 50% MeCN/H₂O (0.1% HCOOH) over 15 min.




Figure SI-53. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.




Table 2, entry 16: 20 mg of **9** (4 μ mol) was weighed out into a 2 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-Pro-OH and 1 equiv of NaSPh were added directly to the resin followed by 600 μ L DMF:H₂O (5:1). Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide **10a-P-OH**.




Figure SI-54. Analytical Column PDA of crude peptide at 254 nm. Gradient: 40-95(10 min)-95(5 min)% MeCN/H₂O (0.1% HCOOH).




Figure SI-55. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.






Table 2, entry 17: 20 mg of **9** (4 μ mol) was weighed out into a 2 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-Pro-OH and 1 equiv of NaSPh were added directly to the resin followed by 600 μ L DMF:H₂O (5:1). Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed, collected, and the resin was subjected to the same reactions conditions for an additional 4 h. After this time, the solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial

solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide **10a-P-OH**.








Figure SI-57. Analytical Column PDA of crude peptide (2) at 254 nm. Gradient: 40-95(10 min)-95(5 min)% MeCN/H₂O (0.1% HCOOH).




Figure SI-58. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.





Table 3, entry 1: 20 mg of **9** (4 μ mol) was weighed out into a 2 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-Ile-OH and 1 equiv of NaSPh were added directly to the resin followed by (5:1) 600 μ L DMF:modified NCL buffer (without guanidine). Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. After this time, the solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide **10a-I-OH**.




Figure SI-59. Evaluation of C-terminal alanine epimerization with isoleucine. A) L-Ala crude, B) D-Ala crude, and C) co-injection, gradient of 50% MeCN/H₂O (0.1% HCOOH) over 15 min. *For conversion see Figure SI-32.*




Table 3, entry 2: 10 mg of **9** (2 μ mol) was weighed out into a 2 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-Ile-OH was added directly to the resin followed by (5:1) 300 μ L DMF:modified NCL buffer (without guanidine). Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. After this time, the solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide **10a-I-OH**.




Figure SI-60. Evaluation of C-terminal alanine epimerization with isoleucine. A) D-Ala crude, B) co-injection, and C) L-Ala crude, gradient of 50% MeCN/H₂O (0.1% HCOOH) over 15 min.




Figure SI-61. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.






Table 3, entry 3: 10 mg of **9** (2 μ mol) was weighed out into a 2 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-IIe-OH and 1 equiv NaSPh was added directly to the resin followed by (5:1) 300 μ L DMF:modified NCL buffer (without guanidine). The reaction vial was agitated at ambient temperature for 4 h. After this time, the solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide **10a-I-OH**.








Figure SI-63. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.




Table 3, entry 4: 24 mg of **9** (5 μ mol) was weighed out into a 2 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-IIe-OH was added directly to the resin followed by (5:1) 600 μ L DMF:H₂O. Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. After this time, the solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide **10a-I-OH**.




Figure SI-64. Evaluation of C-terminal alanine epimerization with isoleucine. A) L-Ala crude, B) D-Ala crude, and C) co-injection, gradient of 50% MeCN/H₂O (0.1% HCOOH) over 15 min. *For conversion see Figure SI-26.*




Table 3, entry 5: 10 mg of **9** (2 μ mol) was weighed out into a 2 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-IIe-OH was added directly to the resin followed by (5:1) 300 μ L DMF:H₂O. Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 18 h. After this time, the solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide **10a-I-OH**.




Figure SI-65. Evaluation of C-terminal alanine epimerization with isoleucine. A) L-Ala crude, B) D-Ala crude, and C) co-injection, gradient of 50% MeCN/H₂O (0.1% HCOOH) over 15 min.




Figure SI-66. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.






Table 3, entry 5: 10 mg of **9** (2 μ mol) was weighed out into a 2 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-IIe-OH was added directly to the resin followed by (5:1) 300 μ L DMF:H₂O. Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed, collected, and the resin was subjected to the same reactions conditions for an additional 4 h. After this time, the solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide **10a-I-OH**.








Figure SI-68. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.




Table 3, entry 6: 20 mg of **9** (4 μ mol) was weighed out into a 2 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-Pro-OH and 1 equiv NaSPh was added directly to the resin followed by (5:1) 600 μ L DMF:H₂O. Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. After this time, the solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide **10a-P-OH**.




Figure SI-69. Evaluation of C-terminal alanine epimerization with proline. A) L-Ala crude, B) D-Ala crude, and C) coinjection, gradient of 50% MeCN/H₂O (0.1% HCOOH) over 15 min. *For conversion see Figure SI-55.*






Table 3, entry 7: 10 mg of **9** (2 μ mol) was weighed out into a 2 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-Pro-OH was added directly to the resin followed by (5:1) 300 μ L DMF:H₂O. Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. After this time, the solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide **10a-P-OH**. The ratio of product to acid is 87:17 by PDA (190 nm).








Table 4. LYRAGLRAY elongation to access protected peptide acids.

Table 4, entry 1: 20 mg of **11** (7 μ mol) was weighed out into a 2 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-Gly-OH and 1 equiv of NaSPh were added directly to the resin followed by 600 μ L (5:1) DMF:modified NCL Buffer (see guanidine-free NCL buffer). Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide **12a**.




Figure SI-71. Analytical Column PDA of crude peptide at 254 nm. Gradient: 40-95(10 min)-95(5 min)% MeCN/H₂O (0.1% HCOOH).




Figure SI-72. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.




Table 4, entry 2: 20 mg of **11** (7 μ mol) was weighed out into a 2 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-Ala-OH and 1 equiv of NaSPh were added directly to the resin followed by 600 μ L (5:1) DMF:modified NCL buffer (see guanidine-free NCL buffer). Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide **13a**.




Figure SI-73. Analytical Column PDA of crude peptide at 254 nm. Gradient: 80-95(10 min)-95(5 min)% MeCN/H₂O (0.1% HCOOH).




Figure SI-74. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.




Table 4, entry 3: 20 mg of **11** (7 μ mol) was weighed out into a 2 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-Ile-OH and 1 equiv of NaSPh were added directly to the resin followed by 600 μ L (5:1) DMF:modified NCL Buffer (see guanidine-free NCL buffer). Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide **14a**.




Figure SI-75. Analytical Column PDA of crude peptide at 254 nm. Gradient: 40-95(10 min)-95(5 min)% MeCN/H₂O (0.1% HCOOH).




Figure SI-76. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.




Table 4, entry 4: 100 mg of **11** (35 μ mol) was weighed out into a 5 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-Pro-OH and 1 equiv of NaSPh were added directly to the resin followed by 600 μ L DMF:H₂O (5:1). Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. This 4 h cleavage was repeated on the same resin the following day. The solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide. The crude peptide was purified using RP-HPLC-MS to yield the pure white solid (**15a**) in 9% yield (7.5 mg, 70% HPLC purity).




Figure SI-77. Analytical Column PDA of crude peptide at 254 nm. Gradient: 40-95(10 min)-95(5 min)% MeCN/H₂O (0.1% HCOOH).




Figure SI-78. Analytical Column PDA of mixed peptides, gradient of 40-95(10 min)-95(5 min)% MeCN/H₂O (0.1% HCOOH) over 15 min.




Figure SI-79. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.






Table 4, entry 5: 20 mg of **11** (7 μ mol) was weighed out into a 5 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-Pro-OH was added directly to the resin along with 1 equiv NaSPh followed by 600 μ L DMF:*i*PrOH (5:1). Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide. The crude peptide was analyzed via RP-HPLC-MS.








Figure SI-81. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.




Table 4, entry 6: 100 mg of **11** (35 μ mol) was weighed out into a 5 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-Pro-OH was added directly to the resin followed by 600 μ L DMF:*i*PrOH (5:1). Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. Then 10 equiv of H-Pro-OH was added directly to the resin followed by 600 μ L DMF:*i*PrOH (5:1). Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed and collected with the initial reaction mixture. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide. The crude peptide was purified using RP-HPLC-MS to yield the pure white solid (**15a**) in 11% yield (4.4 mg, >99% HPLC purity and 3.6 mg, 76% HPLC purity).








Figure SI-82. Analytical Column PDA of crude reaction mixture, gradient of 80-80(10 min)-95(5 min)% MeCN/H₂O (0.1% HCOOH) over 15 min.














Figure SI-85. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.




Table 4, entry 7: 20 mg of **11** (7 μ mol) was weighed out into a 5 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-Pro-OH was added directly to the resin along with 1 equiv NaSPh followed by 600 μ L DMF:HFIP (5:1). Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide. The crude peptide was analyzed via RP-HPLC-MS.




Figure SI-86. Analytical Column PDA of crude reaction mixture, gradient of 40-95(10 min)-95(5 min)% MeCN/H₂O (0.1% HCOOH) over 15 min.




Figure SI-87. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.




Table 4, entry 8: 100 mg of **11** (35 μ mol) was weighed out into a 5 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-Pro-OH was added directly to the resin followed by 600 μ L DMF:HFIP (5:1). Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide. The crude peptide was purified using RP-HPLC-MS to yield the pure white solid in 10% yield (7.4 mg, 91% HPLC purity).




Figure SI-88. Analytical Column PDA of mixed peptides, gradient of 80-80(10 min)-95(5 min)% MeCN/H₂O (0.1% HCOOH) over 15 min.





Figure SI-89. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.



^a All reactions were conducted on 10 mg of resin in 300 μ L (5:1) DMF:solvent, rt = 24 ± 1 °C, ^b Conversion based on integration of remaining peptide on activated linker after nucleophile cleavage in MS data,^c Relative ratios of MS/HPLC data.

Table SI-01. Evaluation of epimerization of AWA using alcohol co-solvents.




Table SI-01, entry 1: 9 mg of **9** (2 μ mol) was weighed out into a 2 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-Pro-OH and 1 equiv NaSPh was added directly to the resin followed by (5:1) 300 μ L DMF:*i*PrOH. Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. After this time, the solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide **10a-P-OH**.




Figure SI-90. Evaluation of C-terminal alanine epimerization with proline. A) D-Ala crude, B) co-injection, and C) L-Ala purified, gradient of 50% MeCN/H₂O (0.1% HCOOH) over 15 min.




Figure SI-91. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.




Table SI-01, entry 2: 9 mg of **9** (2 μ mol) was weighed out into a 2 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-Pro-OH and 1 equiv NaSPh was added directly to the resin followed by (5:1) 300 μ L DMF:HFIP. Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. After this time, the solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide **10a-P-OH**.




Figure SI-92. Evaluation of C-terminal alanine epimerization with proline. A) D-Ala crude, B) co-injection, and C) L-Ala purified, gradient of 50% MeCN/H₂O (0.1% HCOOH) over 15 min.




Figure SI-93. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.




Table SI-01, entry 3: 9 mg of **9** (2 μ mol) was weighed out into a 2 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-Pro-OH was added directly to the resin followed by (5:1) 300 μ L DMF:*i*PrOH. Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. After this time, the solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide **10a-P-OH**. The ratio of product to acid to ester is 87:5:8 by PDA (190 nm).




Figure SI-94. Evaluation of C-terminal alanine epimerization with proline. A) D-Ala crude, B) co-injection, and C) L-Ala purified, gradient of 50% MeCN/H₂O (0.1% HCOOH) over 15 min.




Figure SI-95. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.






Table SI-01, entry 4: 9 mg of **9** (2 μ mol) was weighed out into a 2 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-Pro-OH was added directly to the resin followed by (5:1) 300 μ L DMF:HFIP. Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. After this time, the solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide **10a-P-OH**. The ratio of product to acid to ester is 47:3:50 by PDA (190 nm).








Figure SI-97. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.






Table 5. Side-chain protected amino acid elongation of LYRAGLRAY.

Table 5, entry 1: 50 mg of **11** (18 μ mol) was weighed out into a 5 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-Arg(Pbf)-OH was added directly to the resin followed by 600 μ L DMF:HFIP (5:1). Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide **16a**.








Figure SI-99. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.




Table 5, entry 1: 50 mg of **11** (18 μ mol) was weighed out into a 5 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-Lys(Boc)-OH was added directly to the resin followed by 600 μ L DMF:HFIP (5:1). Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with (1:1:3) TFE:AcOH:CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide **17a**. The crude peptide was purified using RP-HPLC-MS to yield the peptide in 5% yield (3.1 mg, 60% HPLC purity).




Figure SI-100. Analytical Column PDA of crude reaction mixture, gradient of 80-80(10 min)-95(5 min)% MeCN/H₂O (0.1% HCOOH) over 15 min.




Figure SI-101. Analytical Column PDA of pure peptide, gradient of 80-80(10 min)-95(5 min)% MeCN/H₂O (0.1% HCOOH) over 15 min.




Figure SI-102. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.






Table 5, entry 3: 50 mg of **11** (18 μ mol) was weighed out into a 5 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-Asp(*t*Bu)-OH was added directly to the resin followed by 600 μ L DMF:HFIP (5:1). Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with (1:1:3) TFE:AcOH:CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide **18a**. The peptide was purified by RP-HPLC-MS to produce the pure peptide **18a** in 7% yield (2.7 mg). **note:* [*M-tBu*]⁺ was observed










Figure SI-104. Analytical Column PDA of pure peptide, gradient of 80-80(10 min)-95(1 min)-95(4 min)% MeCN/H₂O (0.1% HCOOH) over 15 min.




Figure SI-105. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.




Table 5, entry 4: 50 mg of **11** (18 μ mol) was weighed out into a 5 mL reaction vial and swelled in 500 μ L CH₂Cl₂ for 30 min. After swelling the solvent was removed and the resin was activated (See General Procedure). 10 equiv of H-His(Trt)-OH was added directly to the resin followed by 600 μ L DMF:HFIP (5:1). Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H₂O. The resin was further rinsed with (1:1:3) TFE:AcOH:CH₂Cl₂ (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen (LN₂), and lyophilized to yield the crude peptide **19a**.




Figure SI-106. Analytical Column PDA of crude reaction mixture, gradient of 80-80(10 min)-95(1 min)-95(4 min)% MeCN/H₂O (0.1% HCOOH) over 15 min.




Figure SI-107. Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H₂O (0.1% HCOOH) over 15 min.

